Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Valueman who wrote (982)	9/12/2000 10:57:41 PM
From: Pluvia	Respond to of 1766

The burden of proof is on you my friend. The trial results and reduction in viral loads are easily accessed at the Trimeris web site. You seem to have missed the point. There is no "proof in the TRMS pudding". But don't take our word for it, the MD's we spoke with who ran the trials agreed with our report. Feel free to contact them. 1. I have spoken to 4 of the PI's who participated/managed patients in the Phase II T-20 trials. 2. All of them agree the study was flawed because it used two variables. 3. They also agreed results should not have been attributed to T-20 given the Durant study. Once again, I suggest you re-read our report and study the Durant research. findarticles.com Good luck